Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore

      Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore

      Medical Dialogues Bureau24 July 2019 9:30 AM IST
      The firm's India business was up nine per cent year-on-year to Rs 907 crore for the quarter. The US revenues at Rs 376 crore were up by 13 per cent...
      Sanofi strikes deal for US rights to Roche Tamiflu

      Sanofi strikes deal for US rights to Roche Tamiflu

      Medical Dialogues Bureau24 July 2019 9:15 AM IST
      Under the terms of the agreement, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing,...
      Revamped OxyContin was supposed to reduce abuse, but has it?

      Revamped OxyContin was supposed to reduce abuse, but has it?

      Medical Dialogues Bureau24 July 2019 9:00 AM IST
      There's just one problem: Neither the company that makes OxyContin nor the FDA has allowed the experts to see data on whether it reduces...
      Doctors should prescribe only generic medicines: CDSCO Committee

      Doctors should prescribe only generic medicines: CDSCO Committee

      Medical Dialogues Bureau23 July 2019 5:36 PM IST
      The generic medicines are at least 90 per cent cheaper than branded medicines. There are nearly 600 types of generic medicines and about 23 kinds of...
      Cipla subsidiary gets USFDA nod for generic version of Lyrica

      Cipla subsidiary gets USFDA nod for generic version of Lyrica

      Medical Dialogues Bureau23 July 2019 9:55 AM IST
      Cipla said the approved product, Pregabalin Capsules are a generic therapeutic equivalent version of Pfizer's Lyrica.New Delhi: Drug major Cipla...
      GSK Pharma Q1 net profit up 35 percent at Rs 113 crore in FY20

      GSK Pharma Q1 net profit up 35 percent at Rs 113 crore in FY20

      Medical Dialogues Bureau23 July 2019 9:45 AM IST
      Mumbai: GlaxoSmithKline (GSK) Pharmaceuticals on Monday announced a 35 per cent jump in its net profit to Rs 113.5 crore during the first quarter of...
      Laurus Labs, Rising Pharma launches neuropathic pain capsules in US

      Laurus Labs, Rising Pharma launches neuropathic pain capsules in US

      Medical Dialogues Bureau23 July 2019 9:30 AM IST
      Rising Pharmaceuticals has launched a generic version of Lyrica capsules, in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and...
      Gilead licenses respiratory, herpes antiviral research programs from Novartis

      Gilead licenses respiratory, herpes antiviral research programs from Novartis

      Medical Dialogues Bureau23 July 2019 9:15 AM IST
      Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets....
      Bayer sells Dr Scholls footcare brand to US firm for USD 585 million

      Bayer sells Dr Scholls footcare brand to US firm for USD 585 million

      Medical Dialogues Bureau23 July 2019 9:00 AM IST
      Bayer, whose stock has slumped amid lawsuits over an alleged cancer-causing effect of its Roundup weed killer, struck a deal in May to sell the US sun...
      Different claims used by PATANJALI for marketing in India and abroad: USFDA

      Different claims used by PATANJALI for marketing in India and abroad: USFDA

      Medical Dialogues Bureau22 July 2019 1:44 PM IST
      "I observed that the 'Bel Sharbat' and 'Gulab Sharbat' products are sold under the PATANJALI brand name for domestic (India) and international (USA)...
      Dr Reddys closes sale of US rights for neurology products Tosymra, Zembrace Symtouch

      Dr Reddys closes sale of US rights for neurology products Tosymra, Zembrace Symtouch

      Medical Dialogues Bureau22 July 2019 12:31 PM IST
      Under the agreement, Dr Reddy's sold its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan...
      Alembic Pharma gets USFDA approval for Pregabalin Capsules to manage neuropathic pain

      Alembic Pharma gets USFDA approval for Pregabalin Capsules to manage neuropathic pain

      Medical Dialogues Bureau22 July 2019 10:00 AM IST
      The approved Pregabalin Capsules is therapeutically equivalent to the reference listed drug Lyrica Capsules of PF Prism CV.New Delhi: Drug firm...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok